Fujitsu 1FINITY T900 lab trial validates reduced cost per bit for more sustainable, high-performance, high-capacity networking KAWASAKI, Japan, June 4,…
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon…